A Phase 1 interventional study of Intradermal Microdialysis and Brain Blood Flow Tests in Gestational Diabetes Mellitus (GDM), Postpartum Women and Uncomplicated Pregnancy, sponsored by Anna Stanhewicz, PhD. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.
Sponsored by Anna Stanhewicz, PhD · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Diabetes, Gestational with a site in United States — 52 open to participants now, 65 under way, 2 of them phase 3. Diabetes, Gestational · United States.
Among the 251 studies in Diabetes, Gestational with a site in United States, this one is the 94th largest by planned enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2025, is one of 11 in phase 1, reaches primary completion later than 39 of the 64 other live ones, and was the 229th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →52 of the 251 studies in Diabetes, Gestational with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 20–40 · Women only
Medical College of Wisconsin · Sites in United States
Ages 18+ · Women only
Texas A&M University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
University of Hawaii · Sites in United States
Ages 18+ · Women only
University of California, Davis · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 11 · Phase 3 9 · Phase 4 11
First in 2000; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is below the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 80 across the 194 interventional studies, 72 across the 57 observational. Of the 154 that completed or were terminated, 35 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 251 have an industry lead sponsor. The 10 most frequent:
Anna Stanhewicz, PhD is the lead sponsor of 15 studies on the registry; 8 are open to participants now.
Anna Stanhewicz, PhD has 5 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
22 of the studies in Diabetes, Gestational with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356180University of Maryland, BaltimorePhysical Acvitiy in Pregnancy | 2026-12 |
| NCT05909046Ohio State UniversityA Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE | 2026-12 |
| NCT05388643University of Massachusetts, WorcesterEarly Detection of Gestational Diabetes Mellitus in Pregnancy | 2026-12-01 |
| NCT07176793University of California, DavisPregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes | 2026-12-30 |
| NCT05124808Indiana UniversityIntensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 251 studies in Diabetes, Gestational with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gestational Diabetes Mellitus (GDM) currently affects approximately 14% of all pregnancies worldwide. Importantly, the health-related consequences of GDM extend well beyond pregnancy, such that women with a history of GDM have a 40% increased risk of cerebrovascular diseases and a 67% increased risk of dementia, compared to women with a history of uncomplicated pregnancy. Women with a history of GDM have impaired skin microvascular function, compared with women with a history of uncomplicated pregnancy. Therefore, it's likely that GDM results in impaired brain blood vessel function, yet there is little-to-no information regarding the effects of GDM on brain blood vessel health and function after pregnancy.
Therefore, the purpose of the study is to evaluate the effects of GDM on brain blood flow and brain blood vessel function in healthy women with either a history of GDM or uncomplicated pregnancy.
In this study, the investigators will use two different types of ultrasound to non-invasively measure brain blood flow. Brain blood vessel function will be evaluated by examining the brain blood flow responses to increases in carbon dioxide (the increases in carbon dioxide are similar to what is experienced during a breath hold). Additionally, the investigators will compare the brain blood flow results to skin microvascular function to explore potential mechanisms behind possible impairments in brain blood vessel function. Skin microvascular function will be assessed using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) on dime sized areas of the forearm. Finally, for screening purposes and to further explore potential mechanisms behind any potential impairments in brain blood vessel function, the investigators will perform blood draws to determine the metabolic health of the participants and to analyze for substances that influence blood vessel function.
INCLUSION CRITERIA:
EXCLUSION CRITERIA: We exclude participants from both groups for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All women will complete the same protocol, regardless of pregnancy history.
Drug: Intradermal Microdialysis · Other: Brain Blood Flow Tests · Other: Local Heating
A total of three microdialysis sites will be perfused with ringer's solution, L-NAME, or ketorolac (one drug per site). After a baseline period, all three sites will undergo tests of blood vessel function including an acetylcholine dose-response protocol and a test of maximal skin blood flow with sodium nitroprusside.
Participants will complete CO2 breathing procedures to evaluate brain blood vessel health.
A dime-sized heater will be placed on the skin to evaluate cutaneous microvascular function
Stepped hypercapnia-induced change in middle cerebral artery velocity
Middle cerebral artery velocity responses to stepped concentrations of inhaled carbon dioxide gas
Time frame: During the study visit, an average of 5 hours
Hypercapnia-induced change in internal carotid artery diameter
Internal carotid artery shear-mediated dilation response to inhaled carbon dioxide
Time frame: During the study visit, an average of 5 hours
Change in microvascular blood flow response to increasing concentrations of acetylcholine
Cutaneous vascular vasodilator responses to acetylcholine perfusion in lactated Ringer's, ketorolac, and L-NAME treated microdialysis sites.
Time frame: During the study visit, an average of 5 hours
Started Aug 2025 (actual). Primary completion is estimated for Apr 2027, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anna Stanhewicz, PhD